Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study, the first and largest clinical trial of pre-symptomatic Alzheimer's disease, is now widely available to researchers studying the condition. The comprehensive dataset has already yielded key insights about Alzheimer's disease, which affects nearly seven million people in the United States, and sharing the data opens avenues for further progress. A4 researchers screened more than 7,500 people and enrolled 1,169 people with pre-symptomatic Alzheimer's disease.
This stage of this disease, when amyloid protein begins to collect in the brain, but cognitive decline is not yet evident, is seen as an optimal time to intervene and slow progression. The researchers collected a wealth of information from each participant-;including brain scans, blood samples, genetic information and cognitive tests-;over a period of 4.5 years, and up to 8 years in the extension study.
We were able to track decline and gain a much deeper understanding of this stage of the disease. Now, we want to make sure everybody has access to this information. We consider it essential to share all that we've learned with anyone else who can study this.
" Paul Aisen, MD, co-leader of the A4 study and a professor of neurology and founding director of the Alzheimer's Therapeutic Research Institute (ATRI) at the Keck School of Medicine of USC The latest effort is an extension of a long-standing priority of ATRI and the Keck School of Medicine to b.